Influence of External Factors on Skeletal Growth in Youth
|First Received Date ICMJE||March 4, 2008|
|Last Updated Date||May 8, 2017|
|Start Date ICMJE||August 1999|
|Estimated Primary Completion Date||June 2017 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||BMD total body, femoral neck and lumbar spine (L2-L4) measured by Dual Energy X Ray Absorbtiometry [ Time Frame: 15 years ]|
|Original Primary Outcome Measures ICMJE
||Bone mass, bone structure, muscle strength and fractures [ Time Frame: 10 years ]|
|Change History||Complete list of historical versions of study NCT00633828 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
||fat mass, cardiovascular risk factors [ Time Frame: 10 years ]|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Influence of External Factors on Skeletal Growth in Youth|
|Official Title ICMJE||Determinants for Peak Bone Mass, Skeletal Architecture, Fractures, Adipositas and Cardiovascular Risk Factors During Growth and Adulthood|
Prospective study regulation in bone mass, size, architecture, cortical, trabecular bone, soft tissues and risk factors for cardiovascular disease at growth. Determine regulation by environmental factors. Evaluate how training affects the skeleton, soft tissues and cardiovascular risk factors during growth Material/Methods: (i) 500 children in one RCT´s with or without intervention with physical activity (daily scholl physical education) from school start to college. Annual evaluations
The investigators provide increased understanding of the pathophysiology of osteoporosis by determine the mineralization, size- and architecture development during growth and adulthood. Evaluate if intervention program with exercise increase bone strength, muscle mass and reduce fatness and risk factor for cardiovascular disease.
Skeletal growth and the age related bone loss determine who will get osteoporosis (and fractures), but not only bone mass, also skeletal architecture and bone quality influence bone strength. Regulation of the traits differs where hormones, genetics and environmental factors continuously influence the development with different effect during different ages. It is thus imperative to determine the regulators of the traits and evaluate if these can be modified during growth.
Study regulation of bone mass, size, architecture, cortical, trabecular, axial and appendicular bone and soft tissue during growth and aging; evaluate risk factors for cardiovascular disease; determine importance of environmental factors and hereditary factors.
Prospective, controlled exercise intervention study annually following skeletal development in 500children from age 7.
By evaluating skeletal mass/architecture separate we will increase the understanding of the pathophysiology of osteoporosis. The intervention study provide Evidence Based Information as regard the importance of physical activity during growth. The presented Strength Index, where we combine bone mass and skeletal architecture, may predict fractures better than only bone mass.
Determinants for Peak Bone Mass, Skeletal Architecture, Fractures, Adipositas and Cardiovascular Risk Factors During Growth and Adulthood
Aim of the project:
In the THE BUNKEFLO COHORT we determine if the growing skeleton, fat mass and risk factors for cardiovascular disease irreversible can be influenced by environmental influences as exercise and disease.
Bone mass, cortical thickness and bone geometry independently contribute to bone strength, all regulated differently. Thus, the regulation must therefore be trait specific studied as to understand the pathophysiology of osteoporosis as osteoporosis may partly be the result of deficits occurring during growth. We must also better discriminate the different traits building the skeleton. Areal bone mineral density (aBMD), measured by dual X-ray absorptiometry (DXA) the clinically used estimation of bone mass, is an estimate only adjusted for the measured area, not the third dimension (the depth), but aBMD is often uncritically used as a measurement for the "true density". As to predict future fragility fracture, aBMD is acceptable, but for the understanding of reduced bone strength, we must separate the estimation into bone mass, the amount of bone within the skeletal envelope, bone size and skeletal structure (architecture) as these traits are independent associated with fractures.
Preliminary results from our group:
Bone loss by ageing is partly compensated by increased bone size, partly preserving bone strength. This is of relevance as a Strength Index, taking both bone size and bone mass into account, probably predict future fractures better than bone mass. Two years daily school gymnastics enhanced bone mass and bone size, reduce the fatness and cardiovascular risk factors for disease. Exercise increase bone mass also after puberty but the benefit is lost with cessation of exercise. In spite of this have elderly former active individuals less fractures than inactive people.
Research Questions Following Our Hypothesis:
Methods: Skeletal Evaluation: Dual X-ray absorptiometry (DXA, Lunar DPX-L and Lunar Pixi): Quantitative bone mass (aBMD) total body, femoral neck, lumbar spine and regional. Special software determines cortical width, medullar width, cortical density and trabecular density in mid femur. vBMD and skeletal size can be evaluated from existing measurement in femoral neck and third lumbar vertebrae from DXA scan by the method described by Carter. Ultrasound (Lunar Achilles): Qualitative bone mass (aBMD) and bone width calcaneus. Peripheral computed tomography (pQCT): Bone mass, bone size and skeletal structure. Finite element analyses: skeletal strength. Digital radiographs of the hand: Bone size and cortical thickness. Soft tissue Evaluation: DXA (Lunar DPX-L): Quantitative lean body mass and fat mass. Peripheral computed tomography (pQCT): Quantitative lean body mass and fat mass. Muscle function: Cybex apparatus: Qualitative muscle strength in lower extremities. Balance plate and physiotherapists test: Qualitative muscle capacity. Anthropometric evaluation: Electronic scale: Body weight. Holstein Stadiometer: Sitting and standing height. Harpender stadiometer: Segmental extremity length and width. Pubertal status: Tanner. Environmental Evaluation: Questionnaire: life-style, exercise history, nutrition, and hereditary factors. Bone metabolism: Bone formation: Alkaline phosphatase (ALP), isoenzyme of bone specific ALP, osteocalcin (bone GLA protein), procollagen 1 C-terminal propeptic (P1CP). Bone resorption: Hydroxyproline, pyridinoline, deoxypyridinoline, carboxytelopeptid region (ICTP) and aminotelopeptid region (NTX) in blood and urine. Genetics: Polymorphism of Vitamin D receptor gene (VDR), oestrogen receptor gene (ER), androgen receptor gene (AR), human growth hormone gene (GH 1), collagen 1 A gene (COLL1A) and additional bone related genes that will occur the next years. Hormones: Growth hormone, IGF-1, testosterone, estradiol, luteinisating hormone, follicle stimulating hormone, sex hormone binding globulin (SHBG), androstenedione, dehydroepiandrostenedione (DHEAS). Fractures: The fractures are registered in the files at the Dept. of Radiology, MAS where referrals, reports and films are saved since last century. Questionnaire: Epidemiologic fracture screening. Physiologic Evaluation: Blood pressure (rest): Upper right arm. Bicycle test: Max working capacity by evaluating VO2 MAX. and CO2 production in breath. Bio impedance: Fat percent in total body. Spirometry: Static and dynamic lung function measured by the IOS-method. Ultrasound: Volume and wall thickness of heart. Accelerometer: Number of steps during four days is measured within this minicomputer fastened at the wrist belt (evaluate the objective activity level). Blood Evaluation: Lipid profile and glucose - risk factors for cardiovascular disease and metabolic syndrome.
Probands - Work plan:
A. Determinants of Peak Bone Mass/Size/Architecture, Soft Tissue Development and Risk Factors for Cardiovascular disease During Growth Question: Regulation affecting growth and peak bone mass? Can increased exercise increase bone mass, reduce fatness and risk factors for cardiovascular disease? Could individuals with high risk for fractures be predicted already in early ages? Hypothesis: Changes in environmental factors can increase peak bone mass, reduce fatness and risk factors for future cardiovascular disease. Bone mass "track" so that we could already in young years identify individuals with high risk for fractures.
Study cohorts: a. THE BUNKEFLO STUDY: N=500, aged 7, 8, 9, 12 and 15 years at baseline. In the RCT part of the study: n=310 aged 7-8 at baseline. Half with physical activity and health education as intervention, half controls, all annually followed during primary school. Several other scientific institutions from the University of Lund participate as Department of Physiotherapy, Clinical Physiology, Nutritional, Paediatrics, Child Psychiatry, Teacher Training College, and Dental School, all with separate projects within the RCT. Time plan: Baseline measurements in 1999-2000, with annual follow-up measurements throughout the Swedish nine-year primary school. After that, one follow-up during the last year of secondary school (12th grade), and one follow-up at age 23-25.
The studies will increase the understanding of the pathophysiology of osteoporosis. The Strength Index should possibly replace a bone mass measurement in the fracture risk assessment. The intervention studies will provide Evidence Based Information for the importance of exercise.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Prevention
|Intervention ICMJE||Behavioral: Increased physical education in primary school (daily)
Increased physical education in primary school, 40 minutes per day
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Active, not recruiting|
|Estimated Completion Date||December 2018|
|Estimated Primary Completion Date||June 2017 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||6 Years to 16 Years (Child)|
|Accepts Healthy Volunteers||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Not Provided|
|Removed Location Countries|
|NCT Number ICMJE||NCT00633828|
|Other Study ID Numbers ICMJE||NKOISR10002|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Region Skane|
|Study Sponsor ICMJE||Region Skane|
|Collaborators ICMJE||Not Provided|
|PRS Account||Region Skane|
|Verification Date||May 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP